Author:
Chollet P,Amat S,Cure H,de Latour M,Le Bouedec G,Mouret-Reynier M-A,Ferriere J-P,Achard J-L,Dauplat J,Penault-Llorca F
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Belembaogo E, Feillel V, Chollet P, Curé H, Verrelle P, Kwiatkowski F, Achard J-l, Le Bouëdec G, Chassagne J, Bignon Y-J, de Latour M, Lafaye C, Dauplat J (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A (4/5): 896–900
2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16 (1): 93–100
3. Brain E, Garrino C, Misset JL, Carbonero IG, Itzhaki M, Cvitlovic E, Goldschmidt E, Burki F, Regensberg C, Pappo E, Hagipantelli R, Musset M (1997) Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer 79: 1360–1367
4. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16: 223–228
5. Chollet P, Amat S, Penault-Llorca F, Fetissol F, Body G, Mouret-Reynier, Bons JM, Curé H, Dauplat J, Bougnoux P (2000) High pathological response rate induced by primary docetaxel monotherapy in operable breast cancer. Breast Cancer Res Treat 64: 67 [abstract No. 251]
Cited by
200 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献